Direct compression of flufenamic acid veterinary-grade powder into oral tablet matrices is constrained by the compound’s low aqueous solubility, weakly acidic character, and particle-size dependence during compression. A 250 mg tablet strength is referenced in some older veterinary formularies, but the approved strength is jurisdiction-specific and must be confirmed against the target marketing authorization. The API is typically pre-blended in a bin blender running at 10–15 rpm for 15–20 min with microcrystalline cellulose and croscarmellose sodium before magnesium stearate is added. Lubricant addition is restricted to 0.5–1.0% w/w and a final mixing time of 3–5 min, because prolonged lubrication of acidic flufenamic acid crystals can retard disintegration and produce dissolution failures under Ph. Eur. 2.9.3 conditions. Direct compression is generally preferred only when the flufenamic acid particle size distribution is sufficiently narrow; a typical target for a directly compressible grade is a D90 below 125 µm, although the product-specific dissolution requirement may demand micronized material. Compression is performed on a rotary tablet press with 12 mm round tooling; pre-compression force is maintained in the 5–8 kN range, and main compression is adjusted to a hardness range of 60–100 N as a starting point for poorly compressible acidic APIs. Hardness is not an isolated release criterion; it is linked to disintegration time under Ph. Eur. 2.9.1 and friability under Ph. Eur. 2.9.7, which requires not more than 1.0% weight loss for uncoated tablets. Uniformity of dosage units is tested according to Ph. Eur. 2.9.40, while mass uniformity may be applied only where the conditions of Ph. Eur. 2.9.5 are satisfied. Tablet manufacture is conducted under EudraLex Volume 4 Part II Section 12.7 process validation requirements, with in-process sampling and testing documented under principles consistent with 21 CFR 211.110.

What Changes When the Same API Moves from Tablet Compression to Sterile Injectable Manufacturing?

Injectable manufacture alters the primary control parameters from powder flow, compaction, and blend uniformity to sterility assurance, solvent compatibility, particulate load, and container-closure integrity. Flufenamic acid is practically insoluble in water, usually interpreted as <0.1 mg/mL, so a simple aqueous injectable solution cannot be prepared without salt formation or a non-aqueous co-solvent system. Non-aqueous formulations based on propylene glycol, ethanol, and benzyl alcohol have been described for fenamate-type injectables, but published data specifically for flufenamic acid veterinary injection formulations is limited. The exact solvent ratio, final strength, and preservative content must therefore be established through solubility and stability studies within the marketing authorization dossier rather than assumed from related molecules. Older veterinary formularies sometimes list a 50 mg/mL injectable solution, but this concentration must be verified against the target market because flufenamic acid injectable products are not harmonized across major pharmacopoeias.

Where a non-aqueous solution is selected, sterile filtration through a 0.22 µm PVDF or PTFE membrane is generally preferred over terminal steam sterilization. Propylene glycol/ethanol mixtures can develop vapour-pressure and solvent-loss issues during autoclaving at 121 °C for 15 min, and extractables from elastomeric components may increase under terminal heat load. Filtration train design commonly includes a 0.45 µm pre-filter to reduce bioburden and particle challenge before the final sterilising-grade membrane. Filter validation must address extractables, leachables, compatibility, and adsorption of flufenamic acid onto the membrane surface; adsorption losses can be significant for low-solubility weak acids in high-percentage organic phases. Filling takes place under Grade A conditions with a Grade B background according to EudraLex Volume 4 Annex 1; Grade A zones must meet ISO 14644-1 class 5 limits at rest and in operation. Container-closure integrity is tested after filling because non-aqueous solvents may interact with rubber stoppers and cause swelling or extractables. Residual solvent levels from the formulation are controlled under ICH Q3C and VICH GL18, with ethanol and propylene glycol assigned to appropriate solvent classes based on the final veterinary product dose. Elemental impurity control follows ICH Q3D or the applicable VICH implementation. Release testing includes sterility, bacterial endotoxins, visible particles, assay, related substances, pH where applicable, and residual moisture if the formulation contains water. The sterile injectable route is justified only where rapid onset or avoidance of oral administration is required; the operational boundary is defined by solvent toxicity and injection-site tolerance in the target species, both of which must be supported by safety data.

Filling flufenamic acid into hard gelatin capsules demands a particle-size and bulk-density strategy that is fundamentally different from tablet compression. Capsule fill weight is controlled by volume rather than mass, so the powder bed must have stable bulk density, low segregation, and adequate flow under tamping or dosator action. A direct-fill capsule formulation may combine micronized flufenamic acid with lactose monohydrate and pregelatinized starch; the API is frequently targeted to a D90 below 25 µm to improve dissolution without creating excessive cohesion. If micronized flufenamic acid becomes too cohesive, roller compaction or slugging may be introduced to produce uniform granules. Magnesium stearate is restricted to 0.5–1.0% w/w and blended for not more than 5 min to avoid dissolution slowing. Hard gelatin capsule shells require environmental control between 45–55% RH to prevent brittleness or softening; powder moisture should be below 3.0% when gelatin shells are used. Capsule filling equipment operating by tamping pin or dosing disc must be qualified for fill weight and closure; rejecting partially filled or deformed capsules is critical because flufenamic acid is a potent veterinary NSAID and dose accuracy affects safety. Uniformity of mass is tested under Ph. Eur. 2.9.5, content uniformity under Ph. Eur. 2.9.40, and dissolution according to a product-specific validated method because no universal compendial dissolution medium exists for flufenamic acid. The powder blend must also meet Ph. Eur. 2.9.36 flowability requirements if the filler uses gravimetric control rather than volumetric control. The end product is typically a hard capsule for oral administration to horses or cattle in the 100–250 mg range, but the exact strength is dossier-specific.

Granulation Binder Selection and Residual Moisture Control for Flufenamic Acid Veterinary Granules

Wet granulation becomes the preferred route when direct compression cannot deliver the required tablet hardness or when the intended end product is a granule dosed into animal feed or water. The weakly acidic surface of flufenamic acid influences binder selection; povidone K30 is generally compatible, whereas strongly alkaline binders or amine-based additives should be avoided because they can form salts and alter dissolution. An aqueous binder solution containing 3–5% w/w povidone K30 is added under high-shear mixing, and the granulation endpoint is judged by impeller torque or power consumption rather than fixed time alone. The wet mass is dried in a fluid-bed dryer with inlet air temperature 50–60 °C until residual moisture reaches 1.5–2.0%. Drying below 1.5% can increase fines, dusting, and electrostatic charging; drying above 2.0% can cause particle agglomeration and flow blockages during sachet filling. The melting point of flufenamic acid is reported in the range of 132–135 °C, so the drying temperature is well below thermal degradation risk, but local overdrying in the fluid-bed distributor plate zone must be controlled.

After drying, the granules are sieved through 1.0 mm and 0.2 mm screens, and the fine fraction below 0.2 mm is limited to prevent dusting and segregation. Granule particle-size distribution is measured by a validated laser diffraction method, and flowability is assessed under Ph. Eur. 2.9.36. Content uniformity in the final granule blend is tested under Ph. Eur. 2.9.40, and residual moisture is determined by Karl Fischer titration rather than loss on drying, because flufenamic acid granules may contain bound water that is not detected by simple gravimetric methods. The granules can be filled into sachets or unit-dose cups for oral administration; fill weight variation is controlled by Ph. Eur. 2.9.5. Where the granules are intended for addition to feed or water, the particle size must be large enough to reduce dust inhalation by operators and animals but small enough to disperse quickly; a median particle size between 0.3 mm and 0.8 mm is often used. The operational boundary is moisture uptake at high relative humidity; if packaging is not moisture-proof, the granules can absorb water and lose flowability or initiate crystal bridge formation during storage.

In oral powder manufacture, blend uniformity is often the primary failure mode because low-dose flufenamic acid can segregate during sachet filling if the API particle size is poorly matched to the carrier. Flufenamic acid is geometrically diluted into a granulated carrier such as lactose monohydrate or sucrose before final mixing in a twin-ribbon blender. The API particle size is adjusted to match the carrier D50 within a narrow window; if the API D90 exceeds 150 µm, dissolution from an oral powder may become erratic in the animal’s gastrointestinal fluid. Batch records typically specify blending at 10 rpm for 15–30 min after pre-blending; excessive mixing can induce fines, static charge, and particle adhesion to equipment surfaces. The final powder is filled into sachets or jars for oral administration, and fill weight variation is tested under Ph. Eur. 2.9.5. Blend uniformity testing is performed across 10 sampling points drawn from different locations in the blender using a validated analytical method consistent with VICH GL1. Residual solvent control under VICH GL18 applies only if solvent-based granulation or coating is used; most oral powder formulations avoid organic solvents entirely. Packaging must protect from moisture and light because flufenamic acid powder may be hygroscopic under high-humidity conditions and photostability testing is required under VICH GL2 to assign a shelf life. The end product is administered by mixing with feed or by direct oral dosing; the powder is not intended for parenteral use and must carry a species-specific label with a withdrawal period where applicable.

When the API Is Built into a Medicated Premix Rather Than a Finished Oral Powder

Medicated premix production is controlled in the EU by Regulation (EU) 2019/4, and national feed rules apply elsewhere. Flufenamic acid is not automatically authorized for feed use in every jurisdiction; any food-producing animal application requires confirmation of maximum residue limits in the target market, and flufenamic acid may be absent from some MRL tables. If a flufenamic acid premix is manufactured under a valid authorization, the API is first diluted onto a carrier such as calcium carbonate, wheat middlings, or lactose. Carrier selection depends on bulk density and particle form; a carrier with a bulk density below 0.6 g/cm³ may segregate more readily during pneumatic conveying, while a dense carrier above 1.0 g/cm³ may cause settling and poor flow in feed mill dosing systems. The premix is mixed to achieve a coefficient of variation of not more than 5.0% across ten samples drawn from different points in the blender; this homogeneity limit is consistent with feed-medication quality expectations, although the exact acceptance criterion must be defined in the dossier.

Cross-contamination control is a critical operational boundary. Flufenamic acid residues in subsequent non-medicated feed batches can pose a risk to non-target species, so cleaning validation must demonstrate that residues are below a scientifically justified carryover limit. Published data for flufenamic acid premix carryover limits is limited, and the acceptable carryover value must be established substance-specifically under Regulation (EU) 2019/4. Dedicated or segregated production equipment may be required if cleaning cannot reliably reduce residues. The premix is incorporated into final feed at a rate determined by the prescribed daily dose and animal bodyweight; each batch of medicated feed must be labeled with active substance identity, concentration, target species, and withdrawal period. The premix itself must meet particle-size distribution, bulk density, flowability, and assay uniformity tests before release. Unlike finished oral powders, premixes are not administered directly; they are intermediate products for feed mills or on-farm mixing, and their quality is judged by the homogeneity of the final medicated feed after dilution.

Solution-stable salt formation changes the solubility profile of flufenamic acid in oral drench systems.

Oral solutions and drenches require a different formulation logic from solid dosage forms. Flufenamic acid is a weak acid with low intrinsic water solubility; the free acid dissolves only in strongly alkaline media. Salt formation with meglumine, sodium hydroxide, or lysine can raise aqueous solubility, but the resulting solution pH may exceed 8.5, which can irritate oral mucosa or reduce palatability in target species. A buffered system using disodium hydrogen phosphate and citric acid may hold the pH in the 8.0–9.0 range, but chemical stability must be confirmed because alkaline conditions can promote degradation in related fenamates, and published data for flufenamic acid oral drench stability at different pH values is limited. Accelerated stability testing at 40 °C and 75% RH under VICH GL2 is used to assign a provisional shelf life, with photostability testing included where packaging does not provide full light protection. Preservatives such as sodium benzoate or potassium sorbate are pH-dependent; sodium benzoate loses activity below pH 3.0, but this is not relevant in alkaline drench systems. The final solution is filled into amber HDPE or glass bottles, and the fill volume is controlled under Ph. Eur. 2.9.5. Clarity and visible particulates are tested because precipitation of the free acid can occur if the pH drops during storage. The oral drench is not a sterile product unless specifically designated, but bioburden control during manufacturing remains necessary. The operational boundary is pH drift; any increase in dissolved carbon dioxide from headspace or poor sealing can lower pH and precipitate flufenamic acid, causing dose non-uniformity and visible particle failure. Container closure integrity and pH stability at the end of shelf life are therefore release-critical quality attributes for the solution dosage form.